• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Twist Bioscience Corporation

    2/23/26 3:18:24 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TWST alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001753672
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Twist Bioscience Corp
    SEC File Number
    001-38720
    Address of Issuer
    681 GATEWAY BLVD.
    SOUTH SAN FRANCISCO
    CALIFORNIA
    94080
    Phone
    800-719-0671
    Name of Person for Whose Account the Securities are To Be Sold
    Green Paula
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    146568429.856131170402/23/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common02/20/2026Restricted Stock VestingIssuerCheckbox not checked146502/20/2026Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Paula Green
    681 Gateway Blvd
    South San Francisco � CA � 94080
    Common12/08/202587728833.66
    Paula Green
    681 Gateway Blvd
    South San Francisco � CA � 94080
    Common12/22/20252739433.79
    Paula Green
    681 Gateway Blvd
    South San Francisco � CA � 94080
    Common02/03/2026119455611.15

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    02/23/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Paula Green

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $TWST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TWST

    DatePrice TargetRatingAnalyst
    11/4/2025$41.00Overweight
    Stephens
    12/13/2024$60.00Outperform
    Wolfe Research
    6/4/2024$53.00Buy
    Guggenheim
    1/17/2024$25.00 → $45.00Neutral → Buy
    Goldman
    9/27/2023$27.00Buy
    Berenberg
    1/5/2023$33.00Sector Outperform
    Scotiabank
    1/3/2023$28.00 → $36.00In-line → Outperform
    Evercore ISI
    3/2/2022Outperform
    Cowen
    More analyst ratings

    $TWST
    SEC Filings

    View All

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    2/23/26 3:18:24 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Twist Bioscience Corporation

    144 - Twist Bioscience Corp (0001581280) (Subject)

    2/23/26 3:18:25 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation

    SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    2/17/26 4:21:50 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Twist Bioscience with a new price target

    Stephens initiated coverage of Twist Bioscience with a rating of Overweight and set a new price target of $41.00

    11/4/25 7:44:48 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Twist Bioscience with a new price target

    Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00

    12/13/24 8:32:53 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Twist Bioscience with a new price target

    Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00

    6/4/24 7:44:10 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Twist Bioscience to Present at Upcoming Investor Conferences

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 in Boston, MA; fireside chat at 1:50 pm Eastern Time Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10 in Miami, FL; fireside chat at 3:00 pm Eastern Time Leerink Global Healthcare Conference on Wednesday, March 11 in Miami, FL; fireside chat at 8:40 am Eastern Time The fireside chats will be webcast

    2/18/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

    B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Bo

    2/17/26 7:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes

    Twist TrueAmp Library Preparation Kit with in-house developed enzymes including new Twist TrueAmp Polymerase Twist PCR-Free WGS Library Preparation Kit designed to meet the needs of the growing whole genome sequencing market New kits compatible with additional Twist NGS Applications tools for complete target enrichment and WGS library prep workflows Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist Tr

    2/10/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP of Human Resources Green Paula sold $2,064,770 worth of shares (39,404 units at $52.40), decreasing direct ownership by 24% to 126,041 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/19/26 4:05:33 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and COO Finn Patrick John sold $3,562,417 worth of shares (68,967 units at $51.65) and exercised 50,505 shares at a strike of $25.46, decreasing direct ownership by 6% to 287,788 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/19/26 4:05:19 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Chess Robert sold $105,402 worth of shares (2,184 units at $48.26), decreasing direct ownership by 9% to 21,084 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/18/26 4:05:06 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Financials

    Live finance-specific insights

    View All

    Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

    B-Body® platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Bo

    2/17/26 7:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the first quarter fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal first quarter 2026 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company's

    2/2/26 7:15:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Announces Preliminary First Quarter Fiscal 2026 Revenue

    Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today announced preliminary, unaudited revenue for the first quarter of fiscal 2026 ended December 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the fiscal 2026 first quarter preliminary, unaudited revenue, or click https://investors.twistbioscience.com/events-and-presentations. Twist will issue its financial results for the first quarter of fiscal 2026 before the opening of the market on February 2, 2026, and will hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Easte

    1/12/26 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Leadership Updates

    Live Leadership Updates

    View All

    Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios

    8/6/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar

    10/15/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Twist Bioscience Appoints Adam Laponis as Chief Financial Officer

    Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him

    1/5/24 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TWST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 2:38:08 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Twist Bioscience Corporation

    SC 13G - Twist Bioscience Corp (0001581280) (Subject)

    11/8/24 9:39:34 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Twist Bioscience Corporation

    SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)

    11/5/24 6:07:26 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care